Introduction
Leading pharmaceutical company’s subsidiary acquired a non-oncology prescription formulations business from Khandelwal Laboratories. The acquisition adds 23 brands, 67 SKUs, and 9 pipeline products, expanding domestic market presence.
Also Read: Avance Technologies stock gains 5% on plan to acquire full stake in Pushpak AI
Share price movement of Aurobindo Pharma
On January 2, 2026, Aurobindo Pharma Ltd opened at ₹1,212.55, up 1.66% from its previous close of ₹1,192.90. The stock reached a high of ₹1,212.55 (1.66%) and a low of ₹1,192.80. By 11:51 AM, it traded at ₹1,209.90, a 1.43% increase, with a market cap of ₹70,271.19 crore.
Auro Pharma Acquires Non-Oncology Business from Khandelwal Labs
Auro Pharma Limited, a wholly owned subsidiary of Aurobindo Pharma, acquired the non-oncology prescription formulations business of Khandelwal Laboratories Private Limited on January 1, 2026. The acquisition was completed as a slump sale.
The acquired business includes 23 brands across 67 SKUs and 9 pipeline products. Key portfolios are anti-infective and pain management. The business generated ₹1,135.3 million turnover and ₹289.9 million EBITDA in FY2024-25.
The business employs around 470 field staff and has over 1,600 stockists. The acquisition adds brands to Auro Pharma’s existing portfolio, expanding its domestic pharmaceutical market presence without requiring regulatory approvals.
Stock performance of Aurobindo Pharma for Period of 1 week, 6 months, and 1 year
Aurobindo Pharma Ltd delivered a -1.09% return over the past week. It gained 0.14% in the past six months and declined 11.6% over the past year.
Also Read: Adani Enterprises shares in green as arm acquires 39% stake in flight simulation firm
Shareholding pattern of Aurobindo Pharma
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 |
| Promoter | 51.80% | 51.80% | 51.80% |
| FII | 14.20% | 14.40% | 15.30% |
| DII | 27.60% | 26.90% | 26.20% |
| Public | 6.40% | 6.90% | 6.60% |
About Aurobindo Pharma
Aurobindo Pharma Ltd (NSE: AUROPHARMA) is engaged in manufacturing and marketing active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company serves domestic and international markets with a diverse pharmaceutical product portfolio.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Aurobindo Pharma Ltd share price going up today?
A: Auro Pharma, subsidiary of Aurobindo Pharma Ltd, acquired Khandelwal Labs’ non-oncology business with 23 brands, 67 SKUs, 9 pipeline products.
Q: What does Aurobindo Pharma Ltd specialize in?
A: Aurobindo Pharma Ltd specializes in manufacturing and marketing active pharmaceutical ingredients, generic drugs, and related pharmaceutical services globally.
Q: What is the 52-week high and low of Aurobindo Pharma Ltd stock?
A: The 52-week high of Aurobindo Pharma Ltd stock is ₹1,364.95 and the low is ₹994.35.
